Our mission is to provide the medical community with educational tools to support their daily clinical practice and the patients they serve.


The introduction of biologic therapies to treat a wide variety of diseases has a significant impact on the way these diseases are treated. However, the high cost of biologics has led to big differences in their adoption across the different jurisdictions partly due to the differences in reimbursement systems. Consequently, many patients eligible, from a clinical perspective, to receive a biologic treatment may not receive the adequate treatment due to cost constraints, which adds to their disease burdens.

Biosimilars are approved by the competent regulatory authorities, including the FDA, based on robust evidence of biosimilarity obtained from comprehensive quality, physicochemical and biological comparisons, together with pharmacokinetic studies and confirmatory clinical efficacy studies. Biosimilars are high quality, affordable alternatives to originator biologics. The potential cost savings from the introduction of biosimilars are believed to help alleviate the ever-increasing pressure on healthcare systems and to benefit patients by shifting resources and allowing more patients eligible for a biologic to be treated in a timely, efficient and sustained manner.

This website has been developed and funded by Biogen and is intended for healthcare professionals in the United States.